Compound Supply. 13 3.1.3 Screening Program Reports. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 3.2 Screening Supplies for Lead Optimization. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.1 Supplies from Aurora. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.2 Shipping. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.2.3 Limited Use. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 3.3
Compound Supply. Allelix shall, at its expense, supply to Aurora Compounds selected by Allelix for a Screening Program. In the event Allelix desires to have Aurora test in a Screening Program a Compound (including a library of compounds) owned, accessed or Controlled by Aurora, the parties agree to negotiate in good faith the terms and conditions under which such compound may be screened. Any compounds supplied by Allelix for use in a Screening Program will be provided to Aurora in 96-well microtiter plates, in the quantities, form and format as agreed by the CC. Aurora agrees not to transfer any compounds received from Allelix for use in connection with the Screening Program to any Third Party or to use such compounds for purposes not contemplated herein without Allelix's prior written consent.
Compound Supply. As soon as a Compound has been designated under the procedures of Section 3.2.3 above, the RMC shall convene to decide the most efficient route to produce sufficient quantities of such Compound, not to exceed [ * ] of such Compound, to give IBP the opportunity to perform the minimum studies required to determine IBP’s interest in obtaining a License to a Compound Set associated with such Compound. If the RMC determines that the most efficient route to make such Compound is via [ * ], the RMC shall so notify IBP in writing, and IBP shall be responsible for producing sufficient quantities of the Compound as reasonably specified by the RMC. However, if the RMC determines that the most efficient route to make such Compound is via [ * ], the RMC shall so notify Diversa in writing, and Diversa shall be responsible for producing and delivering to IBP sufficient quantities of the Compound via [ * ] as reasonably specified by the RMC. IBP shall have a maximum of [ * ] from manufacture or receipt (as applicable) of such applicable quantities of the Compound to carry out such studies. If, within such [ * ] period, IBP determines that such Compound is of interest to IBP, IBP shall promptly notify Diversa in writing as to IBP’s desire to obtain a License to such Compound Set associated with such Compound. Subject to the terms and conditions of this Agreement, upon such written notification, if such Compound is not an Excluded Compound at such time, Diversa shall be deemed to grant a License to the Compound Set with respect to such Compound and Products based thereon as provided in Section 4.1. If Diversa is not so notified within such [ * ] period, however, IBP shall thereafter have no right to License such Compound or the Compound Set with respect to such Compound.
Compound Supply. The Compound(s) generated hereunder shall be the sole and exclusive property of MERCK. PHARMATECH shall deliver to MERCK, * the requested amount, accompanied by a document, in English, describing the * to prepare each * and * to prove chemical identity and confirm overall *. MERCK shall have no obligation to accept or pay for any Compound(s) for which any of this data is not provided. PHARMATECH shall advise MERCK of all quantities of the Compound(s) generated hereunder in excess of the quantities requested by MERCK, which MERCK may agree to purchase at a mutually agreeable discounted price. If MERCK, in its sole discretion, decides not to purchase such additional quantities of any Compound(s), PHARMATECH agrees to dispose of such remaining quantities of the Compound(s), at its own cost and expense, according to instructions from MERCK. In no event shall PHARMATECH have any rights in or to any of the Compound(s) and PHARMATECH shall not retain any of the Compound(s) for its own purposes, or to use on behalf of any third party.
Compound Supply. Merck shall, at its expense, supply Aurora with Compounds selected by Merck for an Aurora Screening Program. In the event that Merck desires to have Aurora test in an Aurora Screening Program a chemical (including a library of chemicals) owned, accessed or Controlled by Aurora, the parties agree to negotiate in good faith the terms and conditions under which such chemicals may be screened. Any Compound supplied by Merck for use in an Aurora Screening Program will be provided in 96-well or 384-well-microtiter plates, in quantities, form and format as agreed by the CSP Steering Committee ("Compound Supply"). Aurora agrees not to transfer the Compound Supply to any Third Party, attempt to analyze the Compound Supply for purposes of determining structure, or to use the Compound Supply for purposes not contemplated herein without Merck's prior written consent. Aurora will return or destroy (at Merck's election) such Compound Supply upon written notice by Merck.
Compound Supply. 2. Capital Expenditures. * * * *.
Compound Supply. Sections 8.1 through 8.5 of the Agreement shall be amended and completely replaced with the following:
Compound Supply. (i) Tier 1. Roche represents and warrants that Exhibit F hereto contains a true and complete list of all existing (as of the Amendment Date) quantities of Tier 1 Program API, intermediates of such API, analytical markers and standards, drug product containing such API, placebo, and PET Ligand (collectively, “Tier 1 Materials”). Within thirty (30) days after the Amendment Date, Roche shall confirm the suitability for clinical use of such Tier 1 Materials by complete specification testing and issuance of a new Certificate of Analysis with an extended retest date, and shall supply all of such Tier 1 Materials (together all associated supporting documentation necessary for quality assessment or regulatory filings) to Synosia at no cost; provided, however, that Roche may retain such quantities of those Tier 1 Materials that are necessary for Roche to complete the Human Validation Study. Synosia shall not administer any such produced Tier 1 Materials to humans prior to testing and release of the same by Xxxxxxx.
Compound Supply. For the initial set of clinical trials in the Field in the Licensed Territory to be performed by Ocera under the License Agreement, Kureha shall manufacture and supply to Ocera a minimum of 120 kg of the Compound (the “Initial Supply”), and subsequently Kureha shall supply such additional amounts of the Compound as Ocera requests, based on the Forecasts (as defined below) and pursuant to purchase orders submitted pursuant to Section 3.1. Kureha will provide the Clinical Supply to Ocera in bulk quantities only; provided, however, that Kureha will provide the Clinical Supply to Ocera in packaged form upon Ocera’s request, subject to mutual agreement of the parties. Kureha agrees to enter into clinical manufacture and supply agreements, with economic and other fundamental terms substantially equivalent to the terms herein, with Sublicensees.
Compound Supply. PD shall *** supply Aurora Compounds selected by PD for an Aurora Screening Program. In the event that PD desires to have Aurora test in an Aurora Screening Program a chemical (including a library of compounds) owned, accessed or Controlled by Aurora, the parties agree to negotiate in good faith the terms and conditions under which such compound may be screened. Any chemical supplied by PD for use in an Aurora Screening Program will be provided in 96-well microtiter plates, in quantities, form and format as agreed by the CSP Steering Committee ("Compound Supply"). Aurora agrees not to transfer the Compound Supply to any Third Party, attempt to analyze the Compound Supply for purposes of determining structure, or to use the Compound Supply for purposes not contemplated herein without PD's written consent. Aurora will return or destroy such Compound Supply upon written notice by PD.
